Navigation Links
New Options for Treatment of RA and Lupus are Focus of Rheumatology Thought Leader Panel
Date:11/6/2009

SCOTTSDALE, Ariz., Nov. 6 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies with a stake in the market for rheumatology therapies, including rheumatoid arthritis (RA) and lupus.

"Of all the diseases rheumatologists treat, lupus still has the highest unmet need," according to MedPredict president Jeffrey Berk. "While many more people have RA than have lupus, lupus kills, and RA doesn't. There are a plethora of good therapies for RA, but few for lupus. This expert panel weighs in on the leading B-cell inhibitors that are in development for lupus, and provides insight into how different lupus trial designs have thus far driven clinical outcomes."

To develop this analysis, entitled "Thought Leader Insight & Analysis: Rheumatology," MedPredict conducted primary interviews with U.S.-based rheumatology thought leaders around the time of the recent American College of Rheumatology 2009 conference.

Some of the issues analyzed in this report:

  • Reactions to pivotal Phase III data supporting GlaxoSmithKline's Benlysta (belimumab) in systemic lupus erythemetosis (SLE).
  • Impact of the FDA's complete response letter rejecting Genentech's application for Rituxan (rituximab) in RA patients who have previously failed DMARD therapy - do thought leaders think PML safety concerns apply to all B-cell inhibitors?
  • Insight into rheumatologists' decision-making process for selecting treatment for RA. How will anti-TNF newcomers fit into the rheumatologist's armamentarium?
  • Role of other mechanisms, including CTLA4, IL-6, IL-17, JAK, Syk, TNF/PDE4, BTK, MEK, and S1P.

Companies/Partnerships mentioned in this report include: Abbott, Alder, Amgen/Pfizer, Arana, Array, AstraZeneca/MedImmune, Bristol-Myers Squibb, Celgene, Centocor/Schering-Plough, Cytopia, Genentech/Roche, Genentech/Roche/Chugai, GlaxoSmithKline/Genmab, GSK/Human Genome Sciences, Incyte, Lexicon, Lilly, Merck, Merck Serono/ZymoGenetics, Novartis, Pharmacyclics, Rigel, UCB, UCB/Immunomedics, Pfizer/Trubion.

This report can be purchased by contacting MedPredict.

About MedPredict

MedPredict (www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.

SOURCE MedPredict


'/>"/>
SOURCE MedPredict
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Radiation Therapy Options in Mesothelioma by Veronica Garza of MD Anderson Sponsored by MesoCare.org
2. Clinical Care Options Launches CCO HIV inPractice, a Unique, Free, Comprehensive Online Resource for Healthcare Providers at the Point of Care
3. October 2009 Mayo Clinic Womens HealthSource Highlights Ductal Carcinoma In Situ, New Hearing Aid Options and Self-Acceptance
4. Survey Reveals Parents Are Eager to Learn about Alternative Medicine Options but Information is Lacking
5. On World Menopause Day, October 18, The International Menopause Society and World Health Organization Urge Women to Learn About Their Options for Dealing With Menopause
6. SIMNSA is added to the Satori Global Network™ in Mexico to Offer U.S. Employers Cross Border Health Benefit Options
7. Proposed Medicare Changes Will Increase Costs to Government, Decrease Options for Patients
8. A Staggering 7 Out of 10 Women Facing Breast Cancer Are Never Told of Their Options
9. EdOptions(TM) Offers Schools Affordable Solution to Ensure Continuity of Learning
10. Study Demonstrates That QVAR(R) is More Cost-Effective Than Other Inhaled Corticosteroid (ICS) Asthma Therapy Options
11. New Directions in Angioedema: A Focus on Supportive Care and Treatment Options
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... 06, 2016 , ... For many years, Andrew G. Zubinas has ... The beauty of the Lithuanian language and its poetry inspired him in ... Zubinas lyrically explores all aspects of a living, breathing forest where nothing ever stays ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy ... through tomorrow, December 6th, sparks a conversation about epilepsy, bearing down on the ... 26 people will be diagnosed with epilepsy within their lifetime. With such a ...
(Date:12/5/2016)... Reading, PA (PRWEB) , ... December 05, 2016 , ... ... partner in the United States and Canada for distribution of their natural fruits ... Hansen colors line is an exciting addition to our Life Sciences product portfolio,” ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Partners ("GPP") portfolio company, today announced it has acquired the assets of ... was previously a subsidiary of Chiltern International and focuses on clinical trial ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... The new ... the individual looking to buy neoprene knee sleeves for lifting and any ... design focuses heavily on two main aspects to provide a higher quality knee sleeve ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Eisai Inc. announced today new analyses and ... of the American Epilepsy Society (AES). ... adjunctive therapy for the treatment of partial onset seizures ... generalized tonic-clonic seizures (PGTC) in patients with epilepsy who ... Important Safety Information for FYCOMPA, including Boxed WARNING for ...
(Date:12/5/2016)... , Dec 5, 2016 Research and ... and Pregnancy Rapid Test Market Size, Share, Development, Growth and Demand ... ... The global female fertility and pregnancy rapid test market is ... global Female fertility and pregnancy rapid test market is witnessing high ...
(Date:12/5/2016)... AVIV, Israel , December 5, 2016 ... to identifying, in-licensing and developing promising therapeutic candidates, presents positive ... for BL-8040, the Company,s leading oncology platform at the ongoing ... in San Diego, California . ... , , ...
Breaking Medicine Technology: